Generic placeholder image

Current Pharmaceutical Analysis

Author(s): Su-hua Zhang , Shan-shan Wei , Zhen-yu Zhu, Ying Chen , Hua-lin Cai and Bi-kui Zhang*

DOI: 10.2174/1573412916666200224104617

DownloadDownload PDF Flyer Cite As
Physicochemical Assessment of Branded and Generic Linezolid Injection from Different Pharmaceutical Manufacturers

Page: [584 - 593] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Background: Up to date, generic linezolid injections produced by Chinese manufacturers were not widely used in clinics in China. Quality evaluation of linezolid injections produced in China is a prerequisite, which has rarely been performed.

Objective: This study aimed to evaluate the quality of branded and generic injections from different manufacturers and to provide a basis for quality control.

Methods: In this study, the content of linezolid, related impurities and enantiomer of linezolid were determined by high-performance liquid chromatography. The content of glucose was determined by the iodine method. The insoluble particles and visible and sub-visible particles were determined by light blockage and lamp test, respectively. Osmotic pressure was determined by the freezing point depression method. The standard solution control method was used to check the color of the injection. Linezolid injections from different manufacturers were evaluated uniformly.

Results: No significant difference was found in the content of linezolid, glucose, related impurities, visible particles, insoluble particles, pH value, and solution color between branded and generic drugs from different manufacturers in China.

Conclusion: The quality of samples from different manufacturers is consistent. Although the physicochemical similarity does not guarantee the bioequivalence of studied branded and generic linezolid injections, the results provide references for further bioequivalence study. Generic injections offer more affordable treatment options for patients with infections than expensive branded drugs.

Keywords: Linezolid, quality assessment, generic, physical property, HPLC, bacterial infections.

Graphical Abstract

[1]
Kempker, J.A.; Martin, G.S. The changing epidemiology and definitions of sepsis. Clin. Chest Med., 2016, 37(2), 165-179.
[http://dx.doi.org/10.1016/j.ccm.2016.01.002] [PMID: 27229635]
[2]
Kumar, A. Early antimicrobial therapy in severe sepsis and septic shock. Curr. Infect. Dis. Rep., 2010, 12(5), 336-344.
[http://dx.doi.org/10.1007/s11908-010-0128-x] [PMID: 21308515]
[3]
Levy Hara, G.; Kanj, S.S.; Pagani, L.; Abbo, L.; Endimiani, A.; Wertheim, H.F.; Amábile-Cuevas, C.; Tattevin, P.; Mehtar, S.; Lopes Cardoso, F.; Unal, S.; Gould, I. Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the antimicrobial stewardship and resistance working groups of the international society of chemotherapy. Int. J. Antimicrob. Agents, 2016, 48(3), 239-246.
[http://dx.doi.org/10.1016/j.ijantimicag.2016.06.015] [PMID: 27502752]
[4]
Lamichhane, S.; Manandhar, N.; Dhakal, S.; Shakya, Y.L. Management and outcome of severe sepsis and septic shock patients. J. Nepal Health Res. Counc., 2018, 16(2), 165-171.
[http://dx.doi.org/10.3126/jnhrc.v16i2.20304] [PMID: 29983431]
[5]
MacArthur, R.D.; Miller, M.; Albertson, T.; Panacek, E.; Johnson, D.; Teoh, L.; Barchuk, W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin. Infect. Dis., 2004, 38(2), 284-288.
[http://dx.doi.org/10.1086/379825] [PMID: 14699463]
[6]
Brickner, S.J.; Barbachyn, M.R.; Hutchinson, D.K.; Manninen, P.R. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J. Med. Chem., 2008, 51(7), 1981-1990.
[http://dx.doi.org/10.1021/jm800038g] [PMID: 18338841]
[7]
Cox, H.; Ford, N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int. J. Tuberc. Lung Dis., 2012, 16(4), 447-454.
[http://dx.doi.org/10.5588/ijtld.11.0451] [PMID: 22325685]
[8]
Ager, S.; Gould, K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect. Drug Resist., 2012, 5, 87-102.
[PMID: 22787406]
[9]
Diekema, D.J.; Jones, R.N. Oxazolidinone antibiotics. Lancet, 2001, 358(9297), 1975-1982.
[http://dx.doi.org/10.1016/S0140-6736(01)06964-1] [PMID: 11747939]
[10]
Jones, R.N.; Ross, J.E.; Bell, J.M.; Utsuki, U.; Fumiaki, I.; Kobayashi, I.; Turnidge, J.D. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn. Microbiol. Infect. Dis., 2009, 65(4), 404-413.
[http://dx.doi.org/10.1016/j.diagmicrobio.2009.10.001] [PMID: 19913683]
[11]
Roger, C.; Roberts, J.A.; Muller, L. Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin. Pharmacokinet., 2018, 57(5), 559-575.
[http://dx.doi.org/10.1007/s40262-017-0601-x] [PMID: 29063519]
[12]
Zahedi Bialvaei, A.; Rahbar, M.; Yousefi, M.; Asgharzadeh, M.; Samadi Kafil, H. Linezolid: a promising option in the treatment of Gram-positives. J. Antimicrob. Chemother., 2017, 72(2), 354-364.
[http://dx.doi.org/10.1093/jac/dkw450] [PMID: 27999068]
[13]
Singh, B.; Nand, A.; Budhwar, V. An update on initiatives taken by indian govenrment to promote generic medicines. IJPRBS, 2015, 4(5), 26-38.
[14]
Guttier, M.C.; Silveira, M.P.T.; Luiza, V.L.; Bertoldi, A.D. Factors influencing the preference for purchasing generic drugs in a Southern Brazilian city. Rev. Saude Publica, 2017, 51, 59.
[http://dx.doi.org/10.1590/s1518-8787.2017051006786] [PMID: 28678909]
[15]
Fujimura, S.; Watanabe, A. Generic antibiotics in Japan. J. Infect. Chemother., 2012, 18(4), 421-427.
[http://dx.doi.org/10.1007/s10156-012-0437-0] [PMID: 22684334]
[16]
Zuluaga, A.F.; Agudelo, M.; Cardeño, J.J.; Rodriguez, C.A.; Vesga, O. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS One, 2010, 5(5), e10744.
[http://dx.doi.org/10.1371/journal.pone.0010744] [PMID: 20505762]
[17]
Vesga, O.; Agudelo, M.; Salazar, B.E.; Rodriguez, C.A.; Zuluaga, A.F. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob. Agents Chemother., 2010, 54(8), 3271-3279.
[http://dx.doi.org/10.1128/AAC.01044-09] [PMID: 20547818]
[18]
Rodriguez, C.A.; Agudelo, M.; Cataño, J.C.; Zuluaga, A.F.; Vesga, O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J. Infect., 2009, 59(4), 277-280.
[http://dx.doi.org/10.1016/j.jinf.2009.08.005] [PMID: 19698745]
[19]
Mastoraki, E.; Michalopoulos, A.; Kriaras, I.; Mouchtouri, E.; Falagas, M.E.; Karatza, D.; Geroulanos, S. Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J. Infect., 2008, 56(1), 35-39.
[http://dx.doi.org/10.1016/j.jinf.2007.09.011] [PMID: 17983660]
[20]
Narayana, ChL.; Suresh, T.; Rao, S.M.; Dubey, P.K.; Babu, J.M. A validated chiral HPLC method for the enantiomeric separation of Linezolid on amylose based stationary phase. J. Pharm. Biomed. Anal., 2003, 32(1), 21-28.
[http://dx.doi.org/10.1016/S0731-7085(03)00031-1] [PMID: 12852445]
[21]
Arnet, I.; Altermatt, M.; Roggo, Y.; Schnetzler, G. Pharmaceutical quality of eight generics of ceftriaxone preparation for injection in Eastern Asia. J. Chemother., 2015, 27(6), 337-342.
[http://dx.doi.org/10.1179/1973947814Y.0000000208] [PMID: 25144924]